The predictive value of the dexamethasone suppression test. A placebo-controlled study

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• The dexamethasone suppression test (DST) is a biomarker used in psychiatric research.
• Understanding predictors of treatment response is crucial for effective depression management.

Purpose of the Study:

• To evaluate the dexamethasone suppression test (DST) as a predictor of treatment response to paroxetine, imipramine, and placebo.
• To determine if DST status influences outcomes in a double-blind, placebo-controlled trial for major depressive disorder.

Main Methods:

• A double-blind, placebo-controlled trial involving 105 out-patients diagnosed with depression.
• Patients underwent the dexamethasone suppression test (DST) prior to treatment.
• Treatment arms included paroxetine HCl, imipramine HCl, and placebo.

Main Results:

• The DST did not predict response to either paroxetine or imipramine.
• A positive DST was associated with a significantly lower response rate to placebo (16%) compared to patients with DST suppression (not explicitly stated but implied by contrast).
• Patients with a positive DST showed a 61% response rate to active drugs versus 16% to placebo.

Conclusions:

• A positive DST is not predictive of response to selective serotonin reuptake inhibitors (SSRIs) like paroxetine or tricyclic antidepressants (TCAs) like imipramine.
• A positive DST suggests that patients may have a poorer response to placebo, indicating a potential need for active pharmacological intervention.
• The DST may serve as a biomarker to guide treatment decisions, favoring active somatic treatments over placebo in certain patient subgroups.